Classic Hodgkin lymphoma / Posted 2 years ago

EuroNet-PHL-C2: Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents

Treatment for Hodgkin lymphoma is often very successful, and has given us high cure rates. Standard treatment is chemotherapy, and in children and young people, additional radiotherapy is sometimes needed. Unfortunately, radiotherapy can lead to long-term side effects, such as cardiovascular system disease and increased risk of secondary cancers later on in life.

In this trial, researchers want to individually tailor treatment for each child and young person, effectively treating Hodgkin lymphoma, but avoiding over-treatment and thereby reducing the late side-effects. the main goal is to further reduce the use of radiotherapy, thereby avoiding the long-term side effects often seen with radiotherapy.

The aim of this study is to:

  • Reduce numbers of children needing radiotherapy and minimise the extent of irradiation
  • Investigate if intensifying chemotherapy in children with intermediate/advanced Hodgkin lymphoma will compensate for the reduction in radiotherapy
  • Inclusion Criteria :
    • You have classical Hodgkin lymphoma confirmed by biopsy.
    • You are willing to use effective contraception during your treatment and for at least one year after treatment, if you are sexually active.
    • You are under 25.
  • Exclusion Criteria :
    • You’ve had chemotherapy or radiotherapy for another cancer.
    • You’ve had previous treatment for classical Hodgkin lymphoma, with the exception of steroids used to control a large tumour.
    • You have nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).
    • You have another cancer as well as classical Hodgkin lymphoma.
    • You have any health problems that your doctor thinks might make it unsafe for you to have the trial treatment.
    • You can’t have any of the trial treatments.
    • You have HIV.
    • You live outside of the countries participating in this trial.
    • You are pregnant or breastfeeding.
    • You are taking part in another clinical trial or have been treated with an experimental treatment in the last 30 days.
  • Study start date : 12/07/2018
  • Study end date : 30/09/2021
  • Wales-Based Study Contact : please speak to your clinician
  • Principal Investigator : Dr Eve Gallop-Evans

No post found